Stay updated on EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page.

Latest updates to the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page now uses a consolidated Locations section listing Florida, Michigan, Oregon, and Texas, replacing the previous per-location pages. The HHS Vulnerability Disclosure link was removed from the footer, and the page version updated to v3.3.3.SummaryDifference0.6%

- Check26 days agoNo Change Detected
- Check48 days agoChange DetectedFooter revision tag updated from v3.2.0 to v3.3.2; no changes to study content or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedDeleted the government funding operating status notice that was previously displayed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check69 days agoChange DetectedThe new screenshot shows minor UI adjustments and reorganization; core study details, eligibility criteria, and outcome measures appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check98 days agoChange DetectedPage now shows version v3.2.0 and a government-operating-status notice; old version v3.1.0 is removed.SummaryDifference5%

- Check105 days agoChange DetectedUpdated the page from version v3.0.2 to v3.1.0, reflecting a new software/document version.SummaryDifference0.1%

Stay in the know with updates to EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EA-2353 Dose Escalation in Retinitis Pigmentosa Clinical Trial page.